Navigation Links
Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
Date:8/7/2014

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.

"We are making progress with the FDA discussing the alternatives for the post-marketing obligation for evaluation of cardiovascular outcomes, and we are confident that we can reach agreement on these final details of the NB32 review," said Michael Narachi, CEO of Orexigen.

 

Financial results for the three months ended June 30, 2014
For the three months ended June 30, 2014, Orexigen reported a net loss of $24.5 million, or $0.21 per share, as compared to a net loss of $18.2 million, or $0.19 per share, for the second quarter of 2013.

Total operating expenses for the second quarter of 2014 were $23.7 million compared to $19.1 million for the second quarter of 2013. This overall increase in operating expenses reflects an increase in raw materials, inventory, and manufacturing-related expenses and in stock based compensation expense. While Orexigen is responsible for manufacturing NB32, Takeda Pharmaceuticals will reimburse Orexigen for manufacturing related costs, including finished goods.

As of June 30, 2014, Orexigen had $31.1 million in cash and cash equivalents and an additional $102.2 million in marketable securities, for a total of $133.3 million. Orexigen is eligible to receive cash milestone payments of $100 million from Takeda Pharmaceuticals, between US approval and first commercial sale of NB32.

NB32 program update:

  • NB32 (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR), an investigational medicine for weight loss and the maintenance of weight loss: In June 2014, the United States Food and Drug Administration (FDA) extended it
    '/>"/>

  • SOURCE Orexigen Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast
    2. Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave
    3. Orexigen Resubmits Contrave New Drug Application
    4. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
    5. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    6. Orexigen Announces Successful Interim Analysis of Contrave Light Study
    7. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
    8. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    9. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    10. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    11. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... MYL ) shareholder vote regarding its planned unsolicited offer ... offer to Perrigo shareholders have always been, and will ... of the value available to Perrigo shareholders, and do ... allowed its shareholders to consider," said Joseph C. ...
    (Date:8/28/2015)... India , August 28, 2015 ... Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by Region ... , Asia-Pacific , and Rest of the ... MarketsandMarkets, The global market for Eubiotics was valued at USD ... 7.05 Billion by 2020, at a CAGR of 7.4% from ...
    (Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
    Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
    ... MOUNTAIN VIEW, Calif., Aug. 12 As more and more ... spinal surgery techniques, the negatives of the spinal fusion market ... five years, the industry expects to see a steady inflow ... in the market. (Logo:   http://www.medicaldevices.frost.com ), ...
    ... Nev., Aug. 13 PDL BioPharma, Inc. (PDL) (Nasdaq: ... and the PDL BioPharma logo are considered trademarks of ... This press release contains forward-looking statements. Each ... results may differ materially from those, express or implied, ...
    Cached Medicine Technology:Frost & Sullivan: Innovative Products and Technologies Strengthen U.S. Spinal Surgery Market 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
    (Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
    (Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
    (Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time ... part with their subsidiary USPI Tenet Health. , The American Heart Association hosts their ... and stroke. They believe that together, a difference can be made. Walkers can participate ...
    (Date:8/28/2015)... Michigan (PRWEB) , ... August 28, 2015 , ... On ... Western Michigan, joined as sponsor of the “Music With A Mission” benefit concert in ... behind the event was to raise money to support music education programs in the ...
    (Date:8/28/2015)... ... , ... Altima Technologies, Inc., the maker of popular NetZoom™ ... and audio-video devices, recently released Visio Stencils for the following product lines: ... VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual Storage Series, ...
    Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
    ... older we get, the ,more difficulty we seem to have remembering ... each morning, but unless we park in the ,same space each ... whether we left the SUV in the second or fifth row. ... and will have forgotten ,their names before the handshake is over. ...
    ... - 13 May 2011 Elsevier, the world,s ... announced today that Syngene, India,s first contract research ... provide unlimited access to Reaxys for all Syngene ... competitiveness and productivity in the ever-expanding and highly ...
    ... , FRIDAY, May 13 (HealthDay News) -- A common ... the development of life-threatening heart arrhythmias (when the heart ... a new study. In pinpointing this gene, ... help doctors determine which patients are likely to benefit ...
    ... Lombard, IL, May 13, 2011 Dynamic chest ... compression has been well studied in events such ... not been studied during chiropractic manipulation. In a ... of Manipulative and Physiological Therapeutics , researchers quantified ...
    ... Ga. In a time of transition for rural ... them stay focused on their goals and avoid potential ... an ongoing University of Georgia study., The study, published ... of Community Psychology, is part of a broader ...
    ... New data offer hints to why Parkinson,s disease so ... say researchers at Washington University School of Medicine in ... communications including the signals that control movement. As Parkinson,s ... problems moving and other symptoms. The new research ...
    Cached Medicine News:Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Gene Variant Linked to Sudden Cardiac Death Risk in Blacks 2Health News:Chiropractic manipulation results in little or no risk of chest injury 2Health News:Study finds youth-mentor relationships particularly helpful for those experiencing hardship 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 3
    ... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
    Uvex Patriot Frame...
    Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
    QualCraft™ Euro Lite has a molded nylon frame that fits most faces. Universal keyhole nose bridge fits narrow to average noses. Available with or without lead vinyl-lined side shields....
    Medicine Products: